The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of the efficacy and safety of gemcitabine plus TH-302 versus gemcitabine alone in previously untreated patients with advanced pancreatic cancer.
M. J. Borad
No relevant relationships to disclose
D. Sigal
No relevant relationships to disclose
H. Uronis
No relevant relationships to disclose
J. Stephenson
No relevant relationships to disclose
N. Bahary
No relevant relationships to disclose
M. U. Rarick
No relevant relationships to disclose
L. C. DeMarco
No relevant relationships to disclose
T. J. Finnegan
No relevant relationships to disclose
E. G. Chiorean
No relevant relationships to disclose
D. P. Ryan
No relevant relationships to disclose
A. L. Cohn
No relevant relationships to disclose
B. K. Ulrich
No relevant relationships to disclose
V. C. Harish
No relevant relationships to disclose
E. N. Anderes
No relevant relationships to disclose
W. W. Ma
No relevant relationships to disclose
P. P. Yu
No relevant relationships to disclose
F. Sinicrope
No relevant relationships to disclose
C. Eng
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
U. K. Sunkara
Employment or Leadership Position - Threshold Pharmaceuticals
Stock Ownership - Threshold Pharmaceuticals
S. G. Reddy
No relevant relationships to disclose